ImmunoGen, Inc.
IMGN · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $4,337,922 | $4,971,226 | $993,976 | $1,256,184 |
| - Cash | $605,535 | $571,987 | $201,249 | $275,138 |
| + Debt | $72,113 | $71,957 | $14,262 | $15,244 |
| Enterprise Value | $3,804,500 | $4,471,196 | $806,989 | $996,290 |
| Revenue | $113,425 | $83,153 | $49,869 | $41,167 |
| % Growth | 36.4% | 66.7% | 21.1% | – |
| Gross Profit | $111,270 | $82,244 | $49,243 | $40,991 |
| % Margin | 98.1% | 98.9% | 98.7% | 99.6% |
| EBITDA | $31,059 | -$1,865 | -$37,929 | -$54,079 |
| % Margin | 27.4% | -2.2% | -76.1% | -131.4% |
| Net Income | $30,748 | -$4,248 | -$40,566 | -$59,008 |
| % Margin | 27.1% | -5.1% | -81.3% | -143.3% |
| EPS Diluted | 0.1 | -0.016 | -0.16 | -0.23 |
| % Growth | 721.1% | 89.9% | 30.4% | – |
| Operating Cash Flow | $2,770 | -$66,741 | -$73,719 | -$60,199 |
| Capital Expenditures | -$1,354 | -$78 | -$209 | -$248 |
| Free Cash Flow | $1,416 | -$66,819 | -$73,928 | -$60,447 |